Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBMI (Emeramide) in COPD: randomized, placebo-controlled, blinded crossover pilot trial
2016-001805-18Phase 2Completed
- Sponsor
- EmeraMed
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of emeramide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by EmeraMed. Primary endpoint: Adverse events (safety and tolerability). Started May 2016; status: completed.
02
Drugs
emeramide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2016-001805-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001805-18.